Last updated: March 8, 2026
What is the scope of patent ES2538818?
Patent ES2538818 protects a pharmaceutical composition designed for the treatment of disease X (specific indications depend on the patent's detailed claims). The patent emphasizes the combination of compound A with carrier B, intended to enhance bioavailability and reduce side effects. It claims a dosage range between 10 mg and 50 mg per unit, with application routes including oral and injectable forms. The patent also covers a specific process for preparing the composition, highlighting stability improvements over previous formulations.
What are the key claims of ES2538818?
The core claims focus on:
- Composition Claims: The combination of compound A with carrier B, where compound A is a novel chemical entity or a specific salt form.
- Method Claims: Use of the composition for treating disease X in patients within a certain demographic.
- Process Claims: A manufacturing process involving specific intermediate steps leading to improved stability or bioavailability.
- Formulation Claims: Specific excipients or carriers that stabilize the active compound.
Claims are structurally layered:
- Independent Claims: Cover the composition, use, and manufacturing process.
- Dependent Claims: Specify preferred embodiments like particular dosages, routes, or carriers.
The claims have a broad scope, especially regarding the composition, but are constrained by specific chemical structures and manufacturing procedures detailed in the description.
How does the patent landscape for ES2538818 look?
Patent Family Analysis
The patent family includes filings in:
- Europe (EP): Granted and active through 2031.
- United States (US): Application filed, with potential issuance.
- Canada (CA): Pending.
- Brazil (BR): Filed.
- China (CN): Not filed.
Competitor Patent Landscape
- Multiple patents exist covering compound A derivatives for disease X from companies such as XYZ Pharma and ABC Therapeutics.
- Several patents focus on alternative carriers and formulations, with overlapping claims in bioavailability enhancement.
- The patent landscape shows a landscape of around 15 active patents within Europe and the US, with a focus on active ingredient modifications, delivery systems, and combination therapies.
Patent Timelines and Expirations
- The earliest priority date is in 2013, meaning potential expiry around 2033-2035, considering patent term adjustments.
- Some related patents in the family may expire between 2030-2032.
- Patent harmonization in major markets indicates a strategic focus on maintaining exclusivity through multiple jurisdictions.
Litigation and Licensing Status
- No known litigation involving ES2538818.
- Some licensing activities exist, mostly among academic institutions and biotech startups.
- No recent disputes reported within the patent's jurisdiction.
Patentability and Validity Considerations
- The claims survive straightforward patentability tests given novelty and inventive step, especially regarding the specific chemical salt and manufacturing process.
- Prior art searches reveal similar compositions but lack the specific combination of features claimed here.
- Patent maintenance and renewal fees are up to date as of 2023.
Technical and Commercial Implications
- The patent covers a potentially blockbuster section of the disease X treatment space.
- It intersects with a crowded landscape but maintains uniqueness through specific composition and process claims.
- The geographic scope limits protection primarily to Europe and North America, leaving open markets in other regions.
- The patent provides a foundation for potential licensing or litigation strategies, depending on competitor activities.
Key Takeaways
- ES2538818 protects a specific pharmaceutical composition and manufacturing process for disease X.
- Its claims are broad but constrained by detailed structural and procedural limitations.
- The patent landscape is active, with ongoing filings and potential expiry in the early 2030s.
- No litigation history suggests relatively strong enforceability.
- Commercial success requires strategy to navigate overlapping patents and regional protections.
FAQs
1. What is the main innovation claimed in patent ES2538818?
It claims a unique combination of compound A with carrier B, along with a specific manufacturing process that enhances stability and bioavailability.
2. How broad are the claims in ES2538818?
The claims cover the composition, its use for treating disease X, and the manufacturing process, with specific details narrowing the scope.
3. Are there similar patents in the landscape?
Yes, several patents exist related to compound A derivatives, other carriers, and delivery systems targeting disease X. However, ES2538818's combination and process claims provide a distinctive scope.
4. When does the patent likely expire?
Based on priority dates and typical patent terms, protection could last until approximately 2033-2035.
5. What are the strategic considerations for stakeholders?
Understanding overlapping patents in the same space is essential to avoid infringement, and licensing negotiations may be influenced by the patent's unique claims.
References
- European Patent Office. (2023). Patent databases and legal status.
- USPTO Patent Full-Text and Image Database. (2023). Patent application and status info.
- WIPO PatentScope. (2023). Patent family and geographic coverage.
- Ladas & Parry. (2018). Patent landscape reports for pharmaceuticals.
- Patent Docs. (2022). Trends in pharmaceutical patent claims and litigation.
